XTX Topco’s Adverum Biotechnologies ADVM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-12,655
Closed -$57.3K 3268
2025
Q3
$57.3K Sell
12,655
-17,100
-57% -$50.4K ﹤0.01% 2148
2025
Q2
$64K Buy
+29,755
New +$83.2K ﹤0.01% 1971
2024
Q1
Sell
-5,110
Closed -$38.5K 1782
2023
Q4
$38.5K Buy
5,110
+1,444
+39% +$13.2K 0.01% 1278
2023
Q3
$55K Buy
3,666
+2,033
+124% +$36.5K 0.01% 1267
2023
Q2
$26K Buy
+1,633
New +$17.2K ﹤0.01% 1300
2022
Q4
Sell
-13,207
Closed -$125K 1082
2022
Q3
$125K Buy
13,207
+9,430
+250% +$124K 0.03% 903
2022
Q2
$45K Buy
+3,777
New +$39.6K 0.02% 750
2022
Q1
Sell
-2,911
Closed -$51K 641
2021
Q4
$51K Buy
+2,911
New +$58.3K 0.03% 557

XTX Topco's ADVM Position: Q4 2025 in Review

XTX Topco sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 12,655 shares — an estimated $57.3K sold.

XTX Topco first reported a position in ADVM in Q4 2021 and held it in 8 quarters. The position peaked at $125K in Q3 2022. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.

  • XTX Topco reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
  • XTX Topco sold 12,655 Adverum Biotechnologies shares in Q4 2025, an estimated $57.3K.
  • XTX Topco first reported a position in Adverum Biotechnologies in Q4 2021 and held it in 8 quarters.
  • XTX Topco's Adverum Biotechnologies position peaked at $125K in Q3 2022.
  • 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.

Based on XTX Topco's 13F filing for Q4 2025, filed 17 Feb 2026.